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Abstract
Background/Aim. Dysautonomia appears in almost all
patients with Parkinson’s disease (PD) in a certain stage of
their condition. The aim of our study was to detect the de-
velopment and type of autonomic disorders, find out the
factors affecting their manifestation by analyzing the poten-
tial association with demographic variables related to clinical
presentation, as well as the symptoms of the disease in a PD
patient cohort. Methods. The patients with PD treated at
the Clinic of Neurology in Belgrade during a 2-year period,
divided into 3 groups were studied: 25 de novo patients, 25
patients already treated and had no long-term levodopa
therapy-related complications and 22 patients treated with
levodopa who manifested levodopa-induced motor compli-
cations. Simultaneously, 35 healthy control subjects,
matched by age and sex, were also analyzed. Results. Auto-
nomic nervous system malfunction was defined by Ewing
diagnostic criteria. The tests, indicators of sympathetic and
parasympathetic nervous systems, were significantly differ-
ent in the PD patients as compared with the controls, sug-
gesting the failure of both systems. However, it was shown,
in the selected groups of patients, that the malfunction of
both systems was present in two treated groups of PD pa-
tients, while de novo group manifested only  sympathetic dys-
function. For this reason, the complete autonomic neu-
ropathy was diagnosed only in the treated PD patients,
while de novo patients were defined as those with the isolated
sympathetic dysfunction. The patients with the complete
autonomic neuropathy differed from the subjects without
such neuropathy in higher cumulative and motor unified
Parkinson’s disease rating score (UPDRS) (p < 0.01), activi-
ties of daily living scores (p < 0.05), Schwab-England scale
(p < 0.001) and Hoehn-Yahr scale. There was no difference
between the patients in other clinical-demographic charac-
teristics (sex, age at the time of diagnosis, actual age, dura-
tion of disease, involved side of the body, pain and freez-
ing), but mini mental status (MMS) score and Hamilton de-
pression and anxiety rating scale were significantly lower (p
< 0.05). Conclusion. Our results confirm a high prevalence
of autonomic nervous system disturbances among PD pa-
tients from the near onset of disease, with a predominant
sympathetic nervous system involvement. The patients who
developed complete autonomic neuropathy (both sympa-
thetic and parasympathetic) were individuals with consider-
able level of functional failure, more severe clinical presen-
tation and the existing anxiety and depression.
Key words:
parkinson disease; autonomic nervous system.
Apstrakt
Uvod/Cilj. Poremeýaji autonomnog nervnog sistema javljaju
se kod gotovo svih obolelih od Parkinsonove bolesti (PB) u
nekom stadijumu njihove bolesti. Cilj našeg istraživanja bio je
da se utvrde pojava i tip autonomnih poremeýaja, kao i fakto-
ri koji utiÿu na njihovu pojavu ispitivanjem potencijalne po-
vezanosti sa demografskim varijablama vezanim za kliniÿku
prezentaciju i simptome bolesti u grupi bolesnika sa PB.
Metode. Ispitivali smo obolele od PB koji su leÿeni u Klinici
za neurologiju u Beogradu u dvogodišnjem periodu, podelje-
ne u tri grupe: 25 de novo bolesnika, 25 obolelih koji su leÿeni i
nisu imali nikakve komplikacije vezane za dugotrajnu prime-
nu levodope i 22 bolesnika na levodopi kod kojih su se poja-
vile motorne komplikacije izazvane levodopom. Istovremeno
je analizirano 35 zdravih (kontrolnih) ispitanika, uparenih
prema uzrastu i polu. Rezultati. Disfunkcija autonomnog
nervnog sistema definisana je prema Ewing-ovim dijagnostiÿ-
kim kriterijumima. Testovi, pokazatelji ispada simpatiÿkog i
parasimpatiÿkog nervnog sistema, bili su statistiÿki znaÿajno
razliÿiti kod obolelih od PB u poredjenju sa kontrolom, što je
sugerisalo poremeýaj oba sistema. Kada su izdvojene pojedineVolumen 71, Broj 4 VOJNOSANITETSKI PREGLED Strana 347
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grupe obolelih, meĀutim, pokazano je da disfunkcija oba sis-
tema postoji kod dve grupe leÿenih od PB, dok je kod de novo,
neleÿenih bolesnika, uoÿen samo poremeýaj simpatiÿkog ner-
vnog sistema. Zbog toga je kompletna autonomna neuropa-
tija dijagnostikovana samo kod leÿenih od PB, dok su de novo
oboleli definisani kao oboleli sa izolovanom simpatiÿkom dis-
funkcijom. Osobe sa kompletnom autonomnom neuropati-
jom razlikovale su se od osoba bez autonomne neuropatije po
višem kumulativnom i motornom unifikovanom skoru za
Parkinsonovu bolest (p < 0,01), skoru aktivnosti svakodnev-
nog života (p < 0,05), Schwab-England skali (p < 0,001) i
procenjenoj težini bolesti prema Hoehn-Yahr-u. Bolesnici se
nisu razlikovali prema drugim kliniÿkodemografskim karakte-
ristikama (pol, uzrast u vreme postavljanja dijagnoze, aktuel-
nom uzrastu, trajanju bolesti, zahvaýenoj strani, bolu i „free-
zing-u“), ali su imali statistiÿki znaÿajno niži mini mentalni
skor (MMS), kao i skor na Hamiltonovoj skali depresivnosti i
anksioznosti (p < 0,05). Zakljuÿak. Rezultati ove studije pot-
vrĀuju visoku prevalenciju poremeýaja autonomnog nervnog
sistema u ranoj fazi bolesti kod obolelih od Parkinsonove
bolesti, sa predominantnom disfunkcijom simpatikusa. Bole-
snici kod kojih se razvila kompletna autonomna neuropatija
(simpatiÿka i parasimpatiÿka) imali su izraženu funkcionalnu
slabost, teže kliniÿke simptome, uz prisustvo anksioznosti i
depresije.
Kljuÿne reÿi:
parkinsonova bolest; nervni sistem, autonomni.
Introduction
Autonomic nervous system dysfunctions have long
been the “cornerstone” of Parkinson’s disease (PD) and mul-
tiple systemic atrophy (MSA), and even currently accepted
criteria of diagnosis and recognition of PD have exactly em-
phasized, as an exclusion symptom, the presence of severe
autonomic neuropathy 
1. Nevertheless, autonomic dysfunc-
tion is being recorded in almost all PD patients in a certain
stage of their disease 
2–4, and a Sydney study has shown that
71% of patients develop, after 15 years of their condition,
autonomic disorders, such as sphincter control dysfunction 
5.
On the other hand, the presence of multiple autonomic disor-
ders has been verified even before development of motor
failures, when they have been accepted as non-motor mani-
festations of already existing disease 
6, and perennial dura-
tion of individual non-motor signs has made them possible
prodromal symptom of the disease 
7.
Autonomic symptoms are consistent with the results
of neuropathological studies and the presence of changes in
hypothalamus, brainstem, intermediolateral cell column,
autonomic ganglia, and myenteric plexus; the theory of
Braak et al. 
8 justifies and explains their appearance early in
the course of disease, given the assumption of the ascend-
ing spread of disease in which the involvement of dorsal
nuclei of the vagus nerve is one of the earliest stages of
disease 
8.
The aim of our study was to detect the occurrence and
type of autonomic nervous system symptoms, to find out
factors influencing their presence, by assessing the relation
with demographic, disease-related and clinical variables in
cohort of PD patients.
Methods
The patients with PD, diagnosed according to the Brain
Bank Criteria 
1, treated at the Institute of Neurology, Clinical
Center of Serbia in the period from 2004 to 2006, and age-
matched controls without PD, were evaluated. Three groups
of PD patients were tested: 25 de novo patients (group I), 25
levodopa treated patients without levodopa-induced motor
complications (group II), and 22 levodopa treated patients
with levodopa-induced motor complications (group III), as
well as 35 age-matched controls (group IV). Among the PD
patients, as well as among the control group, neither diabetes
mellitus nor other vascular risk factors were detected (hy-
pertension, hypercholesterolemia, heart disease and periph-
eral nerve diseases).
After obtaining the informed consent and the approval
of the Ethics Committee of the Faculty of Medicine, Univer-
sity of Belgrade (No. 440/XII-2), all the patients were tested
in Neurocardiology Unit, Clinical Center “Bežanijska kosa”,
Belgrade. All the tests were performed under standardized
conditions, in climate-controlled rooms (temperature 23°C),
in the morning, after a period of relaxation. Tobacco, alco-
hol, caffeine, and medications were not allowed before the
test. Autonomic nervous system dysfunction was diagnosed
by means of cardiovascular reflex tests according to Ewing 
9,
and was considered to exist if, at least, two tests were posi-
tive. Vagal dysfunction was diagnosed using 3 tests: Val-
salva maneuver, deep breathing test and heart rate response
to standing. Sympathetic dysfunction was assessed with 2
tests: blood pressure response to standing, and handgrip test.
A patient is diagnosed as one with autonomic neuropathy
(AN) after having two pathological tests (two sympathetic or
two parasympathetic tests) and as complete autonomic neu-
ropathy (CAN) in case of confirmed both parasympathetic
and sympathetic denervation.
The results of each test were expressed as normal (0),
borderline (1) or abnormal (2), as in reference values ac-
cording to Ewing 
9. Maximal possible cumulative score was
10 (i.e. if all five tests had pathological findings). A cumula-
tive score of 0 or 1 was considered normal, while the score
of 2 or 3 was interpreted as mild autonomic dysfunction. The
patients with scores between 4 and 6 were diagnosed with
moderate dysfunction and those who scored 7 or higher were
considered to have severe autonomic dysfunction.
The Mini Mental State Examination (MMSE) 
10, the 21-
item Hamilton Depression Rating Scale (HDRS) 
11, as well
as Hamilton Anxiety Rating Scale (HARS) 
12 were con-
ducted by the same trained interviewer (MS).
When data collection was completed, the differences
between arithmetic means were assessed by Student’s t-test
and between proportions by Ȥ2 test.Strana 348 VOJNOSANITETSKI PREGLED Volumen 71, Broj 4
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Results
A total of 72 patients as well as 35 age-matched con-
trols agreed to participate in the study by signing the in-
formed consent.
Clinical and demographic data of our PD patients and
the control subjects are shown in Table 1.
Autonomic function tests
Tests for the sympathetic nervous system (SNS)
evaluation were significantly different [hand grip – p <
0.0001; orthostatic hypotension (OH) – p < 0.0001) in com-
parison to the controls, suggesting the sympathetic failure in
parkinsonian patients (p < 0.0001). The same was proved for
the parasympathetic nervous system functions (Valsalva ma-
neuver – p < 0.0001; deep breathing – p < 0.05; standing test
– p < 0.001) (Table 2).
However, when the SNS and parasympathetic nervous
system (PNS) were compared in de novo patients and the
control group, the significance was found in both tests for
SNS (hand grip – p < 0.0001; orthostatic hypotension – p <
0.01), while the significance was irrelevant for PNS (Val-
salva maneuver – p < 0.05; deep breathing – NS; standing –
non significant). The patients with good therapeutical re-
sponse, as well as those with developed complications of le-
vodopa treatment differed from the controls in both SNS (p <
0.0001) and PNS dysfunction (p < 0.0001).
Autonomic neuropathy was established in 44% of the
de novo patients, 88% of the patients with good response to
the therapy and in all the patients with complications of le-
vodopa treatment (on average, 76% of the PD patients).
Complete autonomic neuropathy was not established in the
group I, while 36% and 50% in the groups II and III, respec-
tively, had the dysfunction of both SNS and PNS (on aver-
age, 28% of the PD patients) (Figure 1). The presence of
autonomic neuropathy (p < 0.0001) as well as CAN (p <
0.0001) differed significantly between the groups.
Table 1
Clinical and demographic characteristics of Parkinson’s disease patients
Parameters Group I Group II Group III p
Sex (F:M) 9/16 13/12 9/13 NS
Age at onset (years) 56.9 ± 7.6 57.2 ± 8.2 55.3 ± 6.9 NS
Actual age (years) 57.1 ± 7.2 60.6 ± 8.8 63.0 ± 5.0 NS
Disease duration (months) 4.6 ± 9.7 41.6 ± 39.5 102.2 ± 60.3 < 0.0001
Schwab-England scale 84.4 ± 6.5 70.0 ± 11.2 58.6 ± 11.7 < 0.0001
Hoehn&Yahr scale 1.5 2 3 < 0.0001
UPDRS 26.3 ± 12.8 40.3 ± 17.2 53.2 ± 17.5 < 0.0001
MMS 27.7 ± 1.6 26.5 ± 2.6 25.6 ± 3.4 NS
Hamilton A 5.5 ± 3.3 6.9 ± 3.4 10.1 ± 4.3 < 0.0001
Hamilton D 6.4 ± 3.7 8.4 ± 4.1 10.9 ± 4.4 < 0.0001
Note: results are given as n or ʉ ± SD; UPRDS – Unified Parkinson’s Disease Rating Score; MMS – mini mental state; NS – non
significant; F – female; M – male; group I – de novo patients; group II – levodopa treated patients with no levodopa-induced
motor complications; group III – levodopa treated patients with levodopa-induced motor complications.
Table 2
The tests for evaluation of the sympathetic (SNS) and parasympathetic nervous system (PNS)
symptoms in the Parkinson’s disease (PD) and control groups
Parameters Points PD (n) Control (n) p
SNS
hand grip 0 3 12
15 1 5
26 4 8
< 0.0001
03 4 3 4
11 1 1
orthostatic
hypertension
22 7 0
< 0.0001
07 2 7 DS
16 5 8
< 0.0001
PNS
01 6 1 5
12 5 1 8
Valsalva
maneuver
23 1 2
< 0.0001
04 1 2 8
11 5 6
deep breathing
21 6 1
< 0.05
01 9 2 1
11 5 7
standing
23 8 7
< 0.001
01 7 2 5 DPS
15 5 1 0
< 0.0001
0 – normal; 1 – borderline; 2 – pathological; DS – denervation of the sympathetic nervous system;
DPS – denervation of the parasympathetic nervous system.Volumen 71, Broj 4 VOJNOSANITETSKI PREGLED Strana 349
De Luka RS, et al. Vojnosanit Pregl 2014; 71(4): 346–351.
%
0
20
40
60
80
100
120
group I group II group III
AN
CAN
Fig. 1 – The percentage of patients with autonomic neuropathy
(AN) and complete autonomic neuropathy (CAN).
group I – de novo patients; group II – levodopa treated patients with no
levodopa-induced motor complications; group III – levodopa treated patients
with levodopa-induced motor complications.
Patients with and without complete autonomic
neuropathy
The patients with determined complete autonomic
neuropathy (CAN) significantly differed from those with-
out CAN, according to Schwab-England (p < 0.001) and
Hoehn-Yahr scale (p < 0.01), while there was no difference
in other examined clinical characteristics (sex, age at diag-
nosis, actual age, duration of disease, affected side, pain
and “freezing”). A statistical difference was found in cu-
mulative and motor UPDRS (p < 0.01), as well as in daily
activities score (p < 0.05), when compared the patients with
and without CAN. All the performed mental tests (MMSE,
HDRS and HARS) showed a statistical difference (p <
0.05) between the patients who developed CAN and those
who did not (Table 3).
Discussion
In 1817 James Parkinson described that other than clas-
sical symptomatology, the disease includes dysautonomia as
well (“… the bowels demand stimulating medicines of very
considerable power, … the urine passed involuntarily, … the
saliva is continually draining from the mouth….”) 
13. The
conflicting conclusions were reported in the following dec-
ades. Many researchers stated that there was no direct con-
nection between the autonomic failure and PD 
14, contrary to
others who estimated that 80–90% of all parkinsonian pa-
tients suffered from one or another type of dysautonomia 
15.
Besides conflicting conclusions regarding the presence and
frequency, an important issue was the onset of autonomic
symptoms.
Our results support the view that dysfunction of auto-
nomic nervous system represents important clinical feature
of PD, even in its early phase. It is intriguing that not all
parts of autonomic system were involved equally. In de novo
patients, the tests for sympathetic evaluation showed signifi-
cant difference, while the results for PNS were not statisti-
cally different among the groups, thus defining de novo pa-
tients as those manifesting only sympathetic dysfunction.
Shibata et al. 
16 and Buob et al. 
17 also found considerable
dysfunction of the SNS, even at the initial phase of the disease,
which was confirmed by recent results obtained by Gaenslen
et al. 
6. They demonstrated dysregulation of the heart sympa-
thetic noradrenergic innervation (PET scan using 6-[
18F]
fluorodopamine) even before clinical diagnosis of Parkinson’s
disease. Post-mortem studies of the accidental Lewy bodies in
patients without the clinical features of Parkinson’s disease
showed a decrease in tyrosine hydroxylase immunoreactivity
in the epicardial nervous tissue, which also pointed to early
noradrenergic denervation of the heart 
18. Okada et al. 
19
showed the existence of Lewy body formation in the sinoatrial
ganglion in 33% of patients with idiopathic PD.
In attempt to stress an early manifestation of the auto-
nomic dysfunction, Barbic et al. 
20 compared a control group
and PD individuals with and without orthostatic hypotension
(OH), revealing certain autonomic impairment in non-OH
patients, therefore suggesting that parkinsonian patients
without dysautonomia were somewhere between healthy in-
Table 3
Clinical and demographic characteristics and (complete) autonomic neuropathy
Scores and demographic
characteristics Autonomic neuropathy Complete
autonomic neuropathy p
UPDRS (cumulative) 39.7 ± 21.6 53.7 ± 24.1 < 0.01
UPDRS (mental) 3.5 ± 2.2 4.0 ± 2.3
UPDRS (daily activities) 13.2 ± 7.5 17.7 ± 7.5 < 0.05
UPDRS (motor) 22.9 ± 13.8 32.0 ± 15.6 < 0.01
UPDRS (complications) 4.1 ± 3.6 5.5 ± 3.9
Schwab-England 71.4 ± 15.8 58.9 ± 16.9 < 0.001
Hoehn-Yahr 2 3 < 0.01
MMS 26.9 ± 2.5 25.5 ±  3.2 < 0.05
HARS 7.3 ± 4.0 9.7 ± 5.1 < 0.05
HDRS 8.4 ± 4.4 11.0 ± 5.9 < 0.05
Sex (M/F) 39/19 15/14
Age at onset 59.1 ± 8.1 62.4 ± 8.7
Duration of disease (months) 42.4 ± 53.6 59.8 ± 58.8
Affected side (left/right/both) 2/39/17 7/19/3
Pain (yes/no) 25/33 14/15
Freezing (yes/no) 18/39 14/14
Note: results are given as n or ʉ ± SD; UPDRS – Unified Parkinson’s Disease Rating Score; MMS – mini mental state;
HARS – Hamilton Anxiety Rating Scale; HDRS – Hamilton Depression Rating Scale; M – male; F – female.Strana 350 VOJNOSANITETSKI PREGLED Volumen 71, Broj 4
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dividuals and PD subjects with developed OH. Mihci et al. 
21
reached similar conclusions, emphasizing the need for auto-
nomic assessment, even in the absence of autonomic symp-
toms. Nowadays, it is a possibile to early detect postgangli-
onic sympathetic dysfunction using I-125-MIBG-SPECT 
22.
There are assumptions that the autonomic disturbances
may be prodromal signs of Parkinson’s disease 
23. It is also
considered that constipation is an early manifestation of Park-
inson’s disease and that even men who reported having less
than one bowel movement daily had a risk of developing PD
2.7 times higher than men who had bowel movements on
regular daily basis 
24. It is even believed that the presence of
constipation with the abnormal sense of smell and REM sleep
behavior disorder already represent a defined type of PD 
25.
Interestingly, however, there are people with PD who
have a normal finding of the heart suggesting that the auto-
nomic disturbances (loss of cardiac uptake of 123-I-MIBG)
and nigrostriatal degeneration can exist independently in pa-
tients with PD 
26.
Contrary to previous findings, some researchers 
13, 16 sug-
gest a simultaneous deficit of both divisions of ANS, while
Siddiqui et al. 
27, as well as Buob et al. 
17, claim that the initial
dysfunction is of parasympathetic nature, whereas both SNS
and PNS become involved with the disease evolution.
If we accept the theory of Braak et al. 
8, then a huge
percentage of patients with the autonomic disturbances in de
novo group can be explained by their hypothesis. According
to their proposition of six stages of pathological process, af-
ter the initial degeneration in bulbus olfactorius and anterior
olfactory nucleus, this degeneration, in the next stage,
spreads to the brain stem, the region that supposedly repre-
sents the key role in mediating autonomic phenomena.
An early appearance of autonomic disorders is the rea-
son why sometimes it is not possible to differentiate, on the
basis of positive tests, the multiple system atrophy and
Parkinson’s disease 
28.
The issue of risk factors associated with CAN is also
interesting, because an association between the presence of
autonomic nervous system and disease severity, age at onset
and drug intake is not clear 
29.
The Schwab-England and Hoehn-Yahr scales differ sig-
nificantly parkinsonian patients with complete autonomic neu-
ropathy from those without it. This characterizes individuals
with developed CAN as patients with higher degree of func-
tional impairment and severe clinical status. CAN patients vary
according to the number of UPDRS motor scale items espe-
cially according to postural instability and bradykinesia. This is
consistent with the finding that autonomic disorders are more
common problem in people with PIGD form of the disease 
3.
Interestingly, albeit negative correlation between parkinsonian
symptoms and autonomic failure indicates that patients with
more prominent disorders of gait and stability have more severe
dysautonomia, this connection is lost among our patients when
daily levodopa therapy is taken into consideration.
CAN patients also vary from non-CAN group by the
presence of anxiety and depression. Other clinical and
demographic characteristics did not vary between these two
groups of patients. Verbaan et al. 
30 found that the severity of
the autonomic phenomena was higher in people with the se-
vere motor disorders, depressive symptoms, cognitive im-
poverishment, psychiatric complications, sleep disorders and
excessive day sleepiness.
It was found that the most frequent symptoms in pa-
tients with the autonomic dysfunction are the orthostatic hy-
potension, bladder dysfunction, constipation and erectile
disturbances 
31.
In our study, the patients with CAN were not different
from the patients without CAN by age. Although aging
changes the function of the autonomic nervous system, ac-
cording to many studies, an autonomic failure becomes ap-
parent just after the age of 75 years 
32. In addition, our pa-
tients did not differ by the application and length of dopami-
nomimetic treatment (data not shown), though it has been
described that levodopa aggravates the impairment of the
autonomic control of BP and HR 
29. In our group of patients,
impaired cardiovascular autonomic control was detected
early in the course of PD, when patients were drug naïve.
Contrary, in some reports, the use of levodopa agonists pro-
duced lessening of detrusor hyperreflexia, whereas in others
it provided improvement of voiding difficulty 
31. A large
study of Sakakibara and coworkers 
33 showed that patients
taking levodopa and dopamine agonists had voiding phase
disorder more frequently than those taking levodopa only.
Lucetti et al. 
34 offered an interesting concept after 5-year
follow-up of PD patients with and without autonomic dys-
function. The patients with dysautonomia required earlier
introduction of dopaminergic therapy, which indirectly sug-
gested their rapid deterioration.
Conclusion
Our results confirm a high prevalence of autonomic
nervous system disturbances among Parkinson's disease pa-
tients from the near onset of disease, with a predominant
sympathetic nervous system involvement. The patients who
developed complete autonomic neuropathy (both sympa-
thetic and parasympathetic) were individuals with consider-
able level of functional failure, more severe clinical presen-
tation and the existing anxiety and depression.
Conflict of interest
The authors had no conflict of interest regarding the
material and information presented in the article.
Acknowledgments
This study was supported by the Ministry of Education,
Science and Technological Development of the Republic of
Serbia (grant no. 175090).Volumen 71, Broj 4 VOJNOSANITETSKI PREGLED Strana 351
De Luka RS, et al. Vojnosanit Pregl 2014; 71(4): 346–351.
REFERENCES
1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical
diagnosis of idiopathic Parkinsonism – a clinico-pathological
study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3):
181î4.
2. Wenning GK, Ben-Shlomo Y, Hughes A, Daniel SE, Lees A, Quinn
NP. What clinical features are most useful to distinguish defi-
nite multiple system atrophy from Parkinson’s disease? J Neu-
rol Neurosurg Psychiatry 2000; 68(4): 434î40.
3. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of ortho-
static hypotension in a community based cohort of patients
with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2004;
75(10):1470î1.
4. Kummer A, Teixeira AL. Neuropsychiatry of Parkinson’s dis-
ease. Arq Neuropsiquiatr 2009; 67(3B): 930î9.
5. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The
Sydney multicenter study of Parkinson’s disease: the inevita-
bility of dementia at 20 years. Mov Disord 2008; 23(6):
837î44.
6. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. Cardiac
sympathetic denervation preceding motor signs in Parkinson
disease. Clin Auton Res 2007; 17(2): 118î21.
7. Gaenslen A, Swid I, Liepelt-Scarfone I, Godau J, Berg D. The pa-
tients’ perception of prodromal symptoms before the initial di-
agnosis of Parkinson’s disease. Mov Disord 2011; 26(4):
653î8.
8. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN,
Braak E. Staging of brain pathology related to sporadic Parkin-
son’s disease. Neurobiol Aging 2003; 24(2): 197î211.
9. Ewing DJ. Recent advances in the non-invasive investigation of
diabetic autonomic neuropathy. In: Bannister R, editor. Auto-
nomic failure – a textbook of clinical disorders of autonomic
nervous system. 2nd ed. Oxford: Oxford University Press;
1988.
10. Folstein MF, Folstein SE, McHugh PR. “Mini Mental State”: a
practical method for grading the cognitive state of patients for
the clinician. J Psychiatr Res 1975; 12(3): 189î98.
11. Hamilton M. A rating scale for depression. J Neurol Neurosurg
Psychiatry 1960; 23: 56î62.
12. Hamilton M. The assessment of anxiety states by rating. Br J
Med Psychol 1959; 32(1): 50–5.
13. Zakrzewska-Pniewska B, Jamrozik Z. Are electrophysiological
autonomic tests useful in the assessment of dysautonomia in
Parkinson’s disease? Parkinsonism Relat Disord 2003; 9(3):
179î83.
14. Fischer M, Gemende I, Marsch WC, Fischer PA. Skin function and
skin disorders in Parkinson’s disease. J Neural Transm 2001;
108(2): 205î13.
15. Dewey RB Jr. Autonomic dysfunction in Parkinson’s disease.
Neurol Clin. 2004; 22(3 Suppl): S127î39.
16. Shibata M, Morita Y, Shimizu T, Takahashi K, Suzuki N. Cardiac
parasympathetic dysfunction concurrent with cardiac sympa-
thetic denervation in Parkinson’s disease. J Neurol Sci 2009;
276(1î2): 79î83.
17. Buob A, Winter H, Kindermann M, Becker G, Möller JC, Oertel
WH, et al. Parasympathetic but not sympathetic cardiac dys-
function at early stages of Parkinson's disease. Clin Res Cardiol
2010; 99(11): 701î6.
18. Orimo S, Uchihara T, Nakamura A, Mori F, Kakita A, Wakabaya-
shi K, et al. Axonal Ɯ-synuclein aggregates herald centripetal
degeneration of cardiac sympathetic nerve in Parkinson’s dis-
ease. Brain 2008; 131(Pt 3): 642î50.
19. Okada Y, Ito Y, Aida J, Yasuhara M, Ohkawa S, Hirokawa K.
Lewy bodies in the sinoatrial nodal ganglion: clinicopathologi-
cal studies. Pathol Int 2004; 54(Pt 3): 682î7.
20. Barbic F, Perego F, Canesi M, Gianni M, Biagiotti S, Costatino G, et
al. Early abnormalities of vascular and cardiac autonomic con-
trol in Parkinson’s disease without orthostatic hypotension.
Hypertension 2007; 49(1): 120-126.
21. Mihci E, Kardelen F, Dora B, Balkan S. Orthostatic heart rate
variability analysis in idiopathic Parkinson’s disease. Acta Neu-
rol Scand 2006; 113(5): 288î93.
22. Druschky A, Hilz MJ, Platsch G Radespiel-Tröger M, Druschky K,
Kuwert T, et al. Differentiation of Parkinson’s disease and mul-
tiple system atrophy in early disease stages by means of I-123-
MIBG-spect. J Neurol Sci. 2000; 175(1): 3î12.
23. Goldstein DS, Holmes C, Sewell L, Park MY, Sharabi Y. Sympa-
thetic noradrenergic before striatal dopaminergic denervation:
relevance to Braak staging of synucleinopathy. Clin Auton Res.
2011; 22(1): 57î61.
24. Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb
JD, et al. Frequency of bowel movements and the future risk
of Parkinson’s disease. Neurology 2001; 57(3): 456î62.
25. Langston JW. The Parkinson’s complex: parkinsonism is just
the tip of the iceberg. Ann Neurol 2006; 59(4): 591î6.
26. Miyamoto T, Miyamoto M, Iwanami M, Hirata K. Cardiac 123I-
MIBG accumulation in Parkinson’s disease differs in associa-
tion with REM sleep behaviour disorder. Parkinsonism Relat
Disord 2011; 17(3): 219î20.
27. Siddiqui MF, Rast S, Lynn MJ, Auchus AP, Pfeiffer RF. Auto-
nomic dysfunction in Parkinson’s disease: a comprehensive
symptom survey. Parkinsonism Relat Disord 2002; 8(4):
277î84.
28. Riley DE, Chelimsky TC. Autonomic nervous system testing
may not distinguish multiple system atrophy from Parkinson’s
disease. J Neurol Neurosurg Psychiatry 2003; 74(1): 56î60.
29. Bouhaddi M, Vuillier F, Fortat JO, Capelle S, Henriet MT, Rumbach
L, et al. Impaired cardiovascular autonomic control in newly
and long-term-treated patients with Parkinson’s disease: in-
volvement of L-dopa therapy. Auton Neurosci 2004;
116(1î2): 30î8.
30. Verbaan D, Marinus J, Visser M, van Rooden SM, Stiggelbout AM,
van Hilten JJ. Patient-reported autonomic symptoms in Parkin-
son’s disease. Neurology 2007; 69(4): 333î41.
31. Blackett H, Walker R, Wood B. Urinary dysfunction in Parkin-
son’s disease: a review. Parkinsonism Relat Disord 2009; 15(2):
81î7.
32. Mathias C. Autonomic disorders and their recognition. N Engl
J Med 1997; 336(10): 721î4.
33. Sakakibara R, Shinotoh H, Uchiyama T, Sakuma M, Kashiwado M,
Yoshiyama M, et al. Questionnaire-based assessment of pelvic
organ dysfunction in Parkinson’s disease. Auton Neurosci
2001; 92(1î2): 76î85.
34. Lucetti C, Gambaccini G, Del Dotto P, Ceravolo R, Logi C, Rossi G,
et al. Long-term clinical evaluation in patients with Parkinson’s
disease and early autonomic involvement. Parkinsonism Relat
Disord. 2006; 12(5): 279î83.
Received on June 14, 2012.
Revised on December 12, 2012.
Accepted on January 21, 2013.